PRM
NEUTRALProteome Sciences Appoints New Nominated Adviser and Broker
The healthcare diagnostics company has appointed SP Angel Corporate Finance LLP as its new Nominated Adviser and sole Broker.
Proteome Sciences
2.6000GBX
-7.14%
Market Cap
7.67M
Volume
280.31k
81% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
0.3
Day Range
2.0000p - 2.8000p
52 Week Range
1.3000p2.6000p5.4000p
2.6000p
Upcoming Events
PRM
BADProteome Sciences Reports Mixed H1 2025 Results Amid Market Challenges
The biotech firm reported mixed H1 2025 results, with services growth offset by a sharp decline in TMT sales. Facing market headwinds and cash constraints, the outlook remains challenging.
PRM
NEUTRALProteome Sciences Provides AGM Business Update
The healthcare services provider reports a rebound in demand for its proteomics offerings, with increased customer orders and services.
PRM
BADProteome Sciences Reports Increased Losses Amid Challenging Market Conditions
The proteomics firm reported increased annual losses and declining cash reserves, despite a slight uptick in TMT reagent sales. Management cites challenging market conditions but expresses optimism for future recovery.
PRM
NEUTRALProteome Sciences Announces Year-End Results and Investor Presentation
The healthcare company will announce its 2024 results on April 10th and host an investor presentation on April 11th.
PRM
GOODProteome Sciences Secures Substantial US$1m+ Contract
The diagnostics and research company has secured a substantial contract worth over US$1m from a US biopharmaceutical client, with work expected to be completed in the current and next financial years.
PRM
GOODProteome Sciences Secures Loan Facility, Provides Upbeat Trading Update
The healthcare services provider reports strong growth in orders for its proteomics services, with momentum continuing into 2025 and 2026. The company is securing additional financing to expand capacity to meet demand.
PRM
BADProteome Sciences Struggles with Biotech Slowdown, but Sees Potential in New Product Launches
Proteome Sciences, a provider of contract proteomics services, reports a significant decline in revenue and profitability, raising concerns about its financial stability.
PRM
GOODProteome Sciences Poised for Growth in 2024 with New Offerings and Facility
Proteomics services provider Proteome Sciences reports strong customer interest and growth outlook
PRM
GOODProteome Sciences Secures Substantial Contract for Clinical Trial Services
Proteome Sciences secures major contract for clinical trial services